<DOC>
	<DOCNO>NCT01128075</DOCNO>
	<brief_summary>This multi-center , two-arm non-comparative , observational , 96 week Phase IV study evaluate treatment adherence use RebiSmart™ self-injection Rebif® subject relapse multiple sclerosis ( RMS ) . Subjects confirm diagnosis RMS use McDonald Criteria meet eligibility criterion screen period 28 day provide electronic self-injection device ( RebiSmart™ ) inject Rebif® 96 week . The main purpose study evaluate treatment adherence subject RMS 24 week treatment use RebiSmart™ self-injection Rebif® multi-dose cartridge .</brief_summary>
	<brief_title>Treatment Adherence When Using RebiSmart™ Relapsing Multiple Sclerosis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Males females 18 65 year age . Have RMS accord revise McDonald Criteria . Subject eligible Rebif® therapy accord indication clinical use Rebif® Product Monograph . Be willing able comply protocol requirement duration study . Have give write informed consent prior enter screen period . Must register Rebif® Multiple Support Program . Subjects previously disease modify drug ( DMDs ) must stable experience side effect relate previous DMDs time enrollment study , opinion investigator . Rebif® prescribe per Product Monograph washout period leave discretion investigator . Have disease MS could better explain his/her sign symptom . Receive injectable medication regular basis week prior screen period throughout duration study . The administration single injection treatment prophylaxis condition unrelated subject 's MS ( e.g. , influenza pneumococcus vaccination ) acceptable . Are contraindicate use Rebif® accord Rebif® Product Monograph . Have diagnosis clinically isolated syndrome ( CIS ) . Participation investigational trial prior 30 day Study Day 1 . Any visual physical impairment precludes subject selfinjecting treatment use RebiSmart™ Have receive previous treatment Rebif within 5 year prior screen . Subjects medical , psychiatric condition compromise his/her ability understand subject information , give informed consent , comply study protocol complete study questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>RebiSmart</keyword>
	<keyword>Rebif</keyword>
	<keyword>Adherence</keyword>
	<keyword>Multidose</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>RMS</keyword>
</DOC>